Conventional and alternative matrices for driving under the influence of cannabis: Recent progress and remaining challenges

Bioanalysis

Volumn 2, Issue 4, 2010, Pages 791-806

  Wille, Sarah Mr ^a   Ramírez Fernandez, Maria Del Mar ^a   Samyn, Nele ^a   De Boeck, Gert ^a  

^a National Institute of Criminalistics and Criminology   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

TETRAHYDROCANNABINOL; CANNABIS;

CANNABIS ADDICTION; CANNABIS SMOKING; DRIVING UNDER THE INFLUENCE OF CANNABIS; DRUG LEGISLATION; HUMAN; ORAL FLUID DRUG SCREENING; QUANTITATIVE ANALYSIS; REFERENCE VALUE; REVIEW; RISK FACTOR; SCREENING TEST; SWEAT TEST; CAR DRIVING; CHEMISTRY; METHODOLOGY; STATISTICAL ANALYSIS; SUBSTANCE ABUSE;

AUTOMOBILE DRIVING; CANNABIS; DATA INTERPRETATION, STATISTICAL; HUMANS; SUBSTANCE ABUSE DETECTION; TETRAHYDROCANNABINOL;

EID: 79952466220     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.10.29     Document Type: Review

References (108)

1. World Health Organization. World Report on Road Traffic Injury Prevention. Peden M, Scurfield R, Sleet D et al. (Eds). WHO Press, Geneva, Switzerland, 2004.
2. Scheers M, Verstraete AG, Adriaensen M, Raes E, Tant M. Rijden onder Invloed van Psychoactieve Stoffen: Literatuurstudie en Evaluatie van het Handhavingsbeleid. Academia Press, Ghent, Belgium 1-291 (2006).
3. Kelly E, Darke S, Ross J. A review of drug use and driving: epidemiology, impairment, risk factors and risk perceptions. Drug Alcohol Rev. 23, 319-344 (2004). (Pubitemid 39305501)
4. Elliott S, Woolacott H, Braithwaite R. The prevalence of drugs and alcohol found in road traffic fatalities: a comparative study of victims. Sci. Justice 49,19-23 (2009).
5. Mura P, Chatelain C, Dumestre V et al. Use of drugs of abuse in less than 30-year-old drivers killed in a road crash in France: a spectacular increase for cannabis, cocaine and amphetamines. Forensic Sci. Int. 160, 168-172 (2006). (Pubitemid 44056007)
6. Jones AW, Holmgren A, Kugelberg FC. Driving under the influence of cannabis: a 10-year study of age and gender differences in the concentrations of tetrahydrocannabinol in blood. Addiction 103, 452-461 (2008). (Pubitemid 351208103)
7. Raes E, Van den Neste T, Verstraete AG. Drug use, impaired driving and traffic accidents. In: EMCDDA Insights Series (No 8). Luxembourg, Luxembourg, 1-196 (2008).
8. Raes E, Verstraete AG. Cannabis and driving: the situation in Europe. Ann. Pharm. Fr. 64, 197-203 (2006). (Pubitemid 43760906)
9. Macdonald S, Anglin-Bodrug K, Mann RE et al. Injury risk associated with cannabis and cocaine use. Drug Alcohol Depend. 72, 99-115 (2003). (Pubitemid 37434002)
10. Ramaekers JG, Berghaus G, Van Laar M, Drummer OH. Dose related risk of motor vehicle crashes after cannabis use. Drug Alcohol Depend. 73, 109-119 (2004). (Pubitemid 38068347)
11. Drummer OH, Gerostamoulos J, Batziris H et al. The involvement of drugs in drivers of motor vehicles killed in Australian road traffic crashes. Accid. Anal. Prev. 36, 239-248 (2004).
12. Walsh JM, De Gier JJ, Christopherson AS, Verstraete AG. Drugs and driving. Traffic Injury Prevention. 5, 241-253 (2004). (Pubitemid 39049928)
13. Asbridge M, Walsh MJ, De Gier JJ, Christopherson AS, Verstraete A. Letter to the editor and reply on: "drugs and driving," traffic injury prevention. Traffic Inj. Prev. 6, 197 (2005).
14. Parliament of Belgium. Wet tot invoering van speekseltesten op drugs in het verkeer (Loi relative à l"introduction des tests salivaires en matière de drogues dans la circulation), 31 Juillet. Belgisch Staatsblad (Moniteur Belge) (2009).
15. Parliament of France. Relative à la conduite sous l"influence de substances ou plantes classes comme stupéfiants. Belgisch Staatsblad (Moniteur Belge) (2003).
16. Parliament of Belgium. Wet tot wijziging van de wet betreffende de politie over het wegverkeer, gecoördineerd op 16 maart 1968 (1) (Loi modifiant la loi relative à la police de la circulation routière, coordonnée le 16 mars 1968), 16 maart (mars). Belgisch Staatsblad (Moniteur Belge) (1999).
17. Ceder G. Drugged driving in Sweden-effects of new legislation concerning zero-tolerance for narcotic drugs. Proceedings of: The 15th International Confernce of Alcohol, Drugs and Traffic Safety (ICADTS). Stockholm, Sweden, 22-26 May 2000.
18. Steinmeyer S, Ohr H, Maurer HJ, Moeller MR. Practical aspects of roadside tests for administrative traffic offences in Germany. Forensic Sci. Int. 121, 33-36 (2001). (Pubitemid 32758811)
19. Maurer HH, Sauer C, Theobald DS. Toxicokinetics of drugs of abuse: current knowledge of isoenzymes involved in the human metabolism of tetrahydrocannabinol, cocaine, heroin, morphine, and codeine. Ther. Drug. Monit. 28(3), 447-453 (2006). (Pubitemid 44314935)
20. Musshoff F, Madea B. Review of biologic matrices (urine, blood, hair) as indicators of recent or ongoing cannabis use. Ther. Drug Monit. 28(2), 155-163 (2006). (Pubitemid 44314942)
21. Goodwin RS, Gustafson RA, Barnes A, Nebro W, Moolchan ET, Huestis MA. D9-tetrahydrocannabinol, 11-hydroxy-D 9-tetrahydrocannabinol and 11-nor-9- carboxy-D9-tetrahydrocannabinol in human plasma after controlled oral administration of cannabinoids. Ther. Drug Monit. 28(4), 545-551 (2006). (Pubitemid 44181489)
22. Schwilke EW, Karschner EL, Lowe RH et al. Intra- and inter-subject whole blood/plasma cannabinoid ratios determined by 2-dimensional, electron impact GC-MS with cryofocusing. Clin. Chem. 55(6), 1188-1195 (2009).
23. Toennes SW, Ramaekers JG, Theunissen EL, Moeller MR, Kauert GF. Comparison of cannabinoid pharmacokinetic properties in occasional and heavy users smoking a marijuana or placebo joint. J. Anal. Toxicol. 32, 470-477 (2008).
24. Moore C, Coulter C, Rana S, Vincent M, Soares J. Analytical procedure for the determination of the marijuana metabolite 11-nor-D9-tetrahydrocannabinol-9- carboxylic acid in oral fluid specimens. J. Anal. Toxicol. 30, 409-412 (2006). (Pubitemid 44371480)
25. Day D, Kuntz DJ, Feldman M. Detection of THCA in oral fluid by GC-MS/MS. J. Anal. Toxicol. 30, 645-650 (2006). (Pubitemid 44913015)
26. Moore C, Rana S, Coulter C. Simultaneous identification of 2-carboxy-tetrahydrocannabinol, tetrahydrocannabinol, cannabinol and cannabidiol in oral fluid. J. Chromatogr. B. 852, 459-464 (2007). (Pubitemid 46830152)
27. Kauert GF, Ramaekers JG, Schneider E, Moeller MR, Toennes SW. Pharmacokinetic properties of D9-tetrahydrocannabinol in serum and oral fluid. J. Anal. Toxicol. 31, 288-293 (2007). (Pubitemid 46911627)
28. Niedbala RS, Kardos KW, Fritch DF et al. Detection of marijuana use by oral fluid and urine analysis following single-dose administration of smoked and oral marijuana. J. Anal. Toxicol. 25(5), 289-303 (2001). (Pubitemid 32656280)
29. Huestis MA, Cone EJ. Relationship of D9-tetrahydrocannabinol concentrations in oral fluid and plasma after controlled administration of smoked cannabis. J. Anal. Toxicol. 28, 394-399 (2004). (Pubitemid 39150355)
30. Drummer OH. Review: pharmacokinetics of illicit drugs in oral fluid. Forensic Sci. Int. 150, 133-142 (2005). (Pubitemid 41583215)
31. Huestis MA, Mitchell JM, Cone EJ. Urinary excretion profiles of 11-nor-9-carboxy-D9- tetrahydrocannabinol in humans after single smoked doses of marijuana. J. Anal. Toxicol. 20, 441-452 (1996). (Pubitemid 26327467)
32. Stahl SM. Stahl"s Essential Psychopharmacology. Cambridge University Press, NJ, USA, 1-1117 (2008).
33. Giroud C, Bollmann M, Thomas A, Mangin P, Favrat B. Consommation de cannabis: quells sont les risques? Ann. Toxicol. Anal. 20(4), 183-205 (2008).
34. Sewell RA, Poling J, Sofuoglu M. The effect of cannabis compared with alcohol and driving. Am. J. Addiction. 18, 185-193 (2009).
35. Toennes SW, Kauert GF, Steinmeyer S, Moeller MR. Driving under the influence of drugs-evaluation of analytical data of drugs in oral fluid, serum and urine, and correlation with impairment symptoms. Forensic Sci. Int. 152, 149-155 (2005). (Pubitemid 40839281)
36. Papafotiou K, Carter JD, Stough C. The relationship between performance on the standardised field sobriety tests, driving performance and the level of D9-tetrahydrocannabinol (THC) in blood. Forensic Sci. Int. 155, 172-178 (2005). (Pubitemid 41454954)
37. Ramaekers JG, Moeller MR, van Ruitenbeek P, Theunissen EL, Schneider E, Kauert G. Cognition and motor control as a function of D9-THC concentration in serum and oral fluid: limits of impairment. Drug Alcohol Depend. 85, 114-122 (2006). (Pubitemid 44468137)
38. Grotenhermen F, Leson G, Berghaus G et al. Developing limits for driving under cannabis. Addiction 102, 1910-1917 (2007). (Pubitemid 350145667)
39. Moody DE, Monti KM, Crouch DJ. Analysis of forensic specimens for cannabinoids. II. Relationship between blood D9- tetrahydrocannabinol and blood and urine 11-nor-D9-tetrahydrocannabinol-9-carboxylic acid concentrations. J. Anal. Toxicol. 16, 302-306 (1992).
40. Wille SMR, Raes E, Lillsunde P et al. Relationship between oral fluid and blood concentrations of drugs of abuse in drivers suspected of driving under the influence of drugs. Ther. Drug Monit. 31 (4), 511-519 (2009).
41. Toennes SW, Steinmeyer S, Maurer HJ, Moeller MR, Kauert GF. Screening for drugs of abuse in oral fluid-correlation of analysis results with serum in forensic cases. J. Anal. Toxicol. 29, 22-27 (2005). (Pubitemid 40128941)
42. Huestis MA, Scheidweiler KB, Saito T et al. Excretion of D9-tetrahydrocannabinol in sweat. Forensic Sci. Int. 174, 173-177 (2008).
43. Samyn N, De Boeck G, Verstraete AG. The use of oral fluid and sweat wipes for the detection of drugs of abuse in drivers. J. Forensic Sci. 47 (6), 127-134 (2002).
44. Verstraete A, Raes E, Willekens M et al. Rosita-2 Project; Final Report. Academia Press, Gent, Belgium (2006).
45. Verstraete A, Labat L. Use of onsite test for the detection of drugs in oral fluid at the roadside and at the workplace. Ann. Toxicol. Anal. 21(1), 3-8 (2009).
46. Pehrsson A, Gunnar T, Engblom C, Seppä H, Jama A, Lillsunde P. Roadside oral fluid testing: comparison of the results of Drugwipe 5 and Drugwipe benzodiazepines on-site tests with laboratory confirmation results of oral fluid and whole blood. Forensic Sci. Int. 175, 140-148 (2008). (Pubitemid 351199963)
47. Concheiro M, de Castro A, Quintela O, Cruz A, López-Rivadulla M. Confirmation by LC-MS of drugs in oral fluid obtained from roadside testing. Forensic Sci. Int. 170, 156-162 (2007). (Pubitemid 47088884)
48. Laloup M, Ramirez Fernandez M, Wood M, De Boeck G, Maes V, Samyn N. Correlation of D9-tetrahydrocannabinol concentrations determined by LC-MS/MS in oral fluid and plasma from impaired drivers and evaluation of the on-site Dräger DrugTest®. Forensic Sci. Int. 161, 175-179 (2006). (Pubitemid 44142907)
49. Kintz P, Brunet B, Muller JF et al. Evaluation of the Cozart DDSV test for cannabis in oral fluid. Ther. Drug Monit. 31, 131-134 (2009).
50. Crouch J, Walsh JM, Cangianelli L, Quintela O. Laboratory evaluation and field application of roadside oral fluid collectors and drug testing devices. Ther. Drug Monit. 30, 188-195 (2008). (Pubitemid 351521646)
51. Cirimele V, Villain M, Mura P, Bernard M, Kintz P. Oral fluid testing for cannabis: on-site Oraline IV s.a.t. device versus GC/MS. Forensic Sci. Int. 161, 180-184 (2006). (Pubitemid 44142908)
52. Kintz P, Bernhard W, Villain M, Gasser M, Aebi B, Cirimele V. Detection of cannabis use in drivers with the drugwipe device and by GC-MS after Intercept® device collection. J. Anal. Toxicol. 28, 724-727 (2005). (Pubitemid 41803365)
53. Moore C, Ross W, Coulter C et al. Detection of the marijuana metabolite 11-nor-D9- tetrahydrocannabinol-9-carboxylic acid in oral fluid specimens and its contribution to positive results in screening assays. J. Anal. Toxicol. 30, 413-418 (2006). (Pubitemid 44371481)
54. Wille SMR, Samyn N, Ramirez-Fernandez M, De Boeck G. Evaluation of on-site oral fluid screening using drugwipe-5+®, RapidSTAT® and DrugTest 5000® for the detection of drugs of abuse in drivers. Forensic. Sci. Int. (2009) (In Press).
55. Pil K, Raes E, Verstraete A. The toxicological challenges in the European research project DRUID. Forensic Sci. Int. Suppl. Series. 1, 29-32 (2009).
56. Drummer OH, Gerostamoulos D, Chu M, Swann P, Boorman M, Cairns I. Drugs in oral fluid in randomly selected drivers. Forensic Sci. Int. 170, 105-110 (2007). (Pubitemid 47096771)
57. Samyn N, Laloup M, De Boeck G. Bioanalytical procedures for determination of drugs of abuse in oral fluid. Anal. Bioanal. Chem. 388, 1437-1453 (2007). (Pubitemid 47150871)
58. Bosker WM, Huestis MA. Oral fluid testing for drugs of abuse. Clin. Chem. 55(11), 1910-1931 (2009).
59. Maurer HH. Mass spectrometric approaches in impaired driving toxicology. Anal. Bioanal. Chem. 393, 97-107 (2009). (Pubitemid 50257169)
60. Ramirez-Fernandez M, De Boeck G, Wood M, Lopez-Rivadulla M, Samyn N. Simultaneous analysis of THC and its metabolites in blood using liquid chromatography-tandem mass spectrometry. J. Chromatogr. B. 875, 465-470 (2008).
61. Thomas A, Widmer C, Hopfgartner G, Staub C. Fast gas chromatography and negative-ion chemical ionization tandem mass spectrometry for forensic analysis of cannabinoids in whole blood. J. Pharm. Biomed. Anal. 45, 495-503 (2007). (Pubitemid 47588774)
62. Scurlock RD, Ohlson GB, Worthen DK. The detection of D9- tetrahydrocannabinol (THC) and 11-nor-9-carboxy-D 9-tetrahydrocannabinol (THCA) in whole blood using two-dimensional gas chromatography and EI-mass spectrometry. J. Anal. Toxicol. 30, 262-266 (2006). (Pubitemid 44285267)
63. Teixeira H, Verstraete A, Proenua P, Corte-Real F, Monsanto P, Vieira DN. Validated method for the simultaneous determination of D9-THC and D9-THC-COOH in oral fluid, urine and whole blood using solid-phase extraction and liquid chromatography-mass spectrometry with electrospray ionization. Forensic Sci. Int. 170, 148-155 (2007). (Pubitemid 47088879)
64. Schroeder JL, Marinetti LJ, Smith RK, Brewer WE, Clelland BL, Morgan SL. The analysis of D9-tetrahydrocannabinol and metabolite in whole blood and 11-nor- D9- tetrahydrocannabiol-9-carboxylic acid in urine using disposable pipette extraction with confirmation and quantification by gas chromatography-mass spectrometry. J. Anal. Toxicol. 32, 659-666 (2008).
65. Jagerdeo E, Schaff JE, Montgomery MA, LeBeau MA. A semi-automated solid-phase extraction liquid chromatography/tandem mass spectrometry method for the analysis of tetrahydrocannabinol and metabolites in whole blood. Rapid Commun. Mass Spectrom. 23, 2697-2705 (2009).
66. Sergi M, Bafile E, Compagnone D, Curini R, D"Ascenzo G, Romolo FS. Multiclass analysis of illicit drugs in plasma and oral fluids by LC-MS/MS. Anal. Bioanal. Chem. 393, 709-718 (2009). (Pubitemid 50319637)
67. Lowe RH, Karschner EL, Schwilke EW, Barnes AJ, Huestis MA. Simultaneous quantification of D9-tetrahydrocannabinol, 11-hydroxy-D9-tetrahydrocannabinol, and 11-nor-D9-tetrahydrocannabiol-9-carboxylic acid in human plasma using two-dimensional gas chromatography, cryofocusing, and electron impact-mass spectrometry. J. Chromatogr. A 1163, 318-327 (2007). (Pubitemid 47247721)
68. Nadulski T, Sporkert F, Schnelle M et al. Simultaneous and sensitive analysis of THC, 11-OH-THC, THC-COOH, CBD, and CBN by GC-MS in plasma after oral application of small doses of THC and cannabis extract. J. Anal. Toxicol. 29(8), 782-789 (2005). (Pubitemid 41803377)
69. Hunault CC, Mensinga TT, de Vries I et al. D-9-tetrahydrocannabinol (THC) serum concentrations and pharmacological effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg THC. Psychopharmacol. 201, 171-181 (2008).
70. Laloup M, Ramirez-Fernandez M, Wood M et al. Quantitative analysis of D9- tetrahydrocannabinol in preserved oral fluid by liquid chromatography-tandem mass spectrometry. J. Chromatogr. A 1082, 15-24 (2005). (Pubitemid 40848584)
71. Simonin J, Salquebre G, Cirimele V, Kintz P. Criblage de quatre classe de stupéfiants dans la salive par LC-MS/MS. Annal. Toxicol. Anal. 19(2), 141-149 (2007).
72. Øiestad EL, Johansen U, Christophersen AS. Drug screening of preserved oral fluid by liquid chromatography-tandem mass spectrometry. Clin. Chem. 53(2), 300-309 (2007). (Pubitemid 46338275)
73. Concheiro M, de Castro A, Quintela O, Cruz A, López-Rivadulla M. Determination of illicit and medicinal drugs and their metabolites in oral fluid and preserved oral fluid by liquid chromatography-tandem mass spectrometry. Anal. Bioanal. Chem. 391, 2329-2338 (2008).
74. Simões SS, Ajenjo AC, Franco JM, Vieira DN, Dias MJ. Liquid chromatography/ tandem mass spectrometry for the qualitative and quantitative analysis of illicit drugs and medicines in preserved oral fluid. Rapid Commun. Mass Spectrom. 23, 1451-1460 (2009).
75. Badawi N, Simonsen KW, Steentoft A, Bernhoft IM, Linnet K. Simultaneous screening and quantification of 29 drugs of abuse in oral fluid by solid-phase extraction and ultraperformance LC-MS/MS. Clin. Chem. 55(11), 2004-2018 (2009).
76. Moore C, Rana S, Coulter C, Day D, Vincent M, Soares J. Detection of conjugated 11-nor-D9-tetrahydrocannabinol- 9-carboxylic acid in oral fluid. J. Anal. Toxicol. 31, 187-194 (2007). (Pubitemid 46708658)
77. Teixeira H, Proen1a P, Verstraete A, Corte-Real F, Vieira DN. Analysis of D9-tetrahydrocannabinol in oral fluid samples using solid-phase extraction and high-performance liquid chromatography- electrospray ionization mass spectrometry. Forensic Sci. Int. 150, 205-211 (2005). (Pubitemid 41583224)
78. Luo D, Chen F, Xiao K, Feng Y. Rapid determination of D9-tetrahydrocannabinol in saliva by polymer monolith microextraction combined with gas chromatography-mass spectrometry. Talanta 77, 1701-1706 (2009).
79. Pujadas M, Pichini S, Civit E, Santamaria E, Perez K, de la Torre R. A simple and reliable procedure for the determination of psychoactive drugs in oral fluid by gas chromatography-mass spectrometry. J. Pharm. Biomed. Anal. 44, 594-601 (2007). (Pubitemid 46880095)
80. Langel K, Engblom C, Pehrsson A, Gunnar T, Ariniemi K, Lillsunde P. Drug testing in oral fluid-evaluation of sample collection devices. J. Anal. Toxicol. 32, 393-401 (2008).
81. Huestis MA, Cone EJ. Relationship of D9-tetrahydrocannabinol concentrations in oral fluid and plasma after controlled administration of smoked cannabis. J. Anal. Toxicol. 28, 394-399 (2004). (Pubitemid 39150355)
82. Drummer OH. Introduction and review of collection techniques and applications of drug testing of oral fluid. Ther. Drug Monit. 30(2), 203-205 (2008).
83. Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Proposed revisions to mandatory guidelines for federal workplace drug testing programs. 69 FR 19673 (2004).
84. Quintela O, Crouch DJ, Andrenyak DM. Recovery of drugs of abuse from the Immunalysis Quantisal oral fluid collection device. J. Anal. Toxicol. 30, 614-616 (2006). (Pubitemid 44600855)
85. Speedy T, Baldwin D, Jowett G, Gallina M, Jehanli A. Development and validation of the Cozart DDS oral fluid collection device. Forensic Sci. Int. 170, 117-120 (2007). (Pubitemid 47088882)
86. Walsh JM, Verstraete AG, Huestis MA, Merland J. Guidelines for research on drugged driving. Addiction 103(8), 1258-1268 (2008). (Pubitemid 352009056)
87. Huestis MA, ElSohly M, Nebro W, Barnes A, Gustafson RA, Smith ML. Estimating time of last oral ingestion of cannabis from plasma THC and THCCOOH concentrations. Ther. Drug. Monit. 28(4), 540-544 (2006). (Pubitemid 44181488)
88. Cone EJ, Johnson RE, Darwin WD et al. Passive inhalation of marijuana smoke: urinalysis and room air levels of D-9-tetrahydrocannabinol. J. Anal. Toxicol. 11, 89-96 (1987). (Pubitemid 17077484)
89. Perez-Reyes M, DiGuiseppi S, Mason AP, Davis KH. Passive inhalation of marijuana smoke and urinary excretion of cannabinoids. Clin. Pharmacol. Ther. 34, 36-41 (1983). (Pubitemid 13073299)
90. Niedbala S, Kardos K, Salamone S, Fritch D, Bronsgeest M, Cone EJ. Passive cannabis smoke exposure and oral fluid testing. J. Anal. Toxicol. 28, 546-552 (2004). (Pubitemid 39314852)
91. Niedbala SR, Kardos KW, Fritch DF et al. Passive cannabis smoke exposure and oral fluid testing. II. Two studies of extreme cannabis smoke exposure in a motor vehicle. J. Anal. Toxicol. 29, 607-615 (2005). (Pubitemid 41803346)
92. Moody DE, Monti KM, Spanbauer AC. Long-term stability of abused drugs and antiabuse chemotherapeutical agents stored at -20°C. J. Anal. Toxicol. 23, 535-540 (1999). (Pubitemid 29473410)
93. Dugan S, Bogema S, Schwartz RW, Lappas NT. Stability of drugs of abuse in urine samples stored at -20°C. J. Anal. Toxicol. 18, 391-396 (1994). (Pubitemid 24352998)
94. Buddha DP, McKinley RM, Walsh JK, Jamir TS, Past MR. Effect of freezing on the concentration of drugs of abuse in urine. J. Anal. Toxicol. 17, 378-380 (1993). (Pubitemid 23286741)
95. Roth KDW, Siegel NA, Johnson RW, Litauszki L, Salvati L, Harrington CA. Investigation of the effects of solution composition and container material type on the loss of 11-nor-D9-THC-9-carboxylic acid. J. Anal. Toxicol. 20, 291-300 (1996). (Pubitemid 26301184)
96. Skopp G, Pötsch L. Stability of 11-nor-D9- carboxy- tetrahydrocannabinol glucuronide in plasma and urine assessed by liquid chromatography-tandem mass spectrometry. Clin. Chem. 48 (2), 301-306 (2002). (Pubitemid 34107267)
97. Johnson JR, Jennison TA, Peat MA, Foltz RL. Stability of D9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy- THC in blood and plasma. J. Anal. Toxicol. 8(5), 202-204 (1984). (Pubitemid 14035342)
98. Wong AS, Orbanosky W, Reeve VC, Beede JD. Stability of D-9-tetrahydrocannabinol in stored blood and serum. NIDA Res. Monogr. 42, 119-124 (1982). (Pubitemid 13127564)
99. Christophersen AS. Tetrahydrocannabinol stability in whole blood: plastic versus glass containers. J. Anal. Toxicol. 10(4), 129-131 (1986). (Pubitemid 17100544)
100. Toennes S, Kauert GF. Importance of vacutainer selection in forensic toxicological analysis of drugs of abuse. J. Anal. Toxicol. 25, 339-343 (2001). (Pubitemid 32656286)
101. International Organization for Standardisation. General requirements for the competence of testing and calibration laboratories. ISO/IEC 17025 (1999).
102. Ventura M, Pichini S, Ventura R et al. Stability of drugs of abuse in oral fluid collection devices with purpose of external quality assessment schemes. Ther. Drug Monit. 31, 277-280 (2009).
103. Clarke J, Wilson JF. Proficiency testing (external quality assessment) of drug detection in oral fluid. Forensic Sci. Int. 150, 161-164 (2005). (Pubitemid 41583218)
104. Conception and Evaluation of Roadside Testing Instruments to formalise impairment evidence in drivers (CERTIFIED). EU Contract no RO-90-RS 3054 (2000) http://drunkdrivingdefense.com/ publications-articles/european-study-of- ingestion-of-drugs-and-driving-performance.htm (Accessed December 2009)
105. Parliament of Victoria. Road safety (drug driving) Act 2003. 11/2003 (2003) www.austlii.edu.au/au/legis/vic/bill/ rsdb2003257/
106. Knoche A, Bernhoft IM, Mathijssen R et al. Driving under the Influence of Drugs, Alcohol and Medicines (DRUID). Deliverables list. www.druid-project.eu (Accessed December 2009)
107. United Kingdom Laboratory. United Kingdom Laboratory guidelines for legally defensible workplace drug testing. Version 1.0. Urine drug testing (2001) http://ltg.uk.net/pages/monographs/ guidelines.asp
108. Australian Standard®. Procedures for Specimen collection and the detection and quantitation of drugs in oral fluid, AS4760- 2006 www.standards.org.au